The efficacy and the safety of gemcitabine / S-1 combination therapy in patients with advanced non-resectable or post-operative recurrent biliary tract cancer -multicenter phase II study
Phase of Trial: Phase II
Latest Information Update: 03 Jan 2010
At a glance
- Drugs Gemcitabine (Primary) ; Gimeracil/oteracil/tegafur (Primary)
- Indications Biliary cancer
- Focus Adverse reactions; Therapeutic Use
- 03 Jan 2010 Status changed from recruiting to completed as reported by University Hospital Medical Information Network Japan record.
- 07 Feb 2007 New trial record.